Plexiform Bioscience
Dover, US · Founded 2024 · Delaware corporation
Plexiform Bio is developing non-invasive treatments for retinal vascular diseases, which are currently treated primarily through injections into the eye. The company aims to offer alternatives to frequent, uncomfortable eye injections for patients with retinal conditions that cause blurred vision.
Founders & leadership
SA
Saad AhmadinExecutive
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2024
▶$1.3MraisedJul 2025 · 14 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedJul 2025 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Saad AhmadExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $1.3M
- Minimum investment
- $50K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Plexiform Bioscience do?
- Plexiform Bio is developing non-invasive treatments for retinal vascular diseases, which are currently treated primarily through injections into the eye. The company aims to offer alternatives to frequent, uncomfortable eye injections for patients with retinal conditions that cause blurred vision.
- How much funding has Plexiform Bioscience raised?
- Plexiform Bioscience has disclosed $1.3M raised across 1 round.
- Where is Plexiform Bioscience headquartered?
- Plexiform Bioscience is headquartered in Dover, US.